- Home
- DKI vs CLRB Comparison
DKI vs CLRB Comparison
Compare DKI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKI | CLRB |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 12.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | DKI | CLRB |
|---|---|---|
| Price | $4.80 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 76.1K | ★ 143.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $2.20 |
| 52 Week High | $11.80 | $8.05 |
Technical Indicators
Market Signals| Indicator | DKI | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 44.62 |
| Support Level | $0.39 | N/A |
| Resistance Level | $6.80 | $3.01 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 16.15 | 40.68 |
Price Performance
Historical ComparisonAbout DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.